High-accountability psychiatry

Clozapine Treatment and Monitoring in New York

Clozapine is an oral antipsychotic used for treatment-resistant schizophrenia. It also has an indication to reduce recurrent suicidal behaviour in people with schizophrenia or schizoaffective disorder at continuing risk.

FDA removed the Clozapine REMS effective June 13, 2025, so prescribers, pharmacies, and patients no longer enroll or report ANC results through that program. Severe neutropenia remains a boxed-warning risk, and current labeling still recommends baseline and ongoing ANC monitoring. Nao begins with a psychiatric evaluation and record review before assuming treatment.

Clozapine care after REMS removal

Clozapine is an oral medicine for selected treatment-resistant schizophrenia cases and for reducing recurrent suicidal behaviour in schizophrenia or schizoaffective disorder. FDA removed its REMS in June 2025, but blood and other clinical monitoring remain. A treatment plan includes baseline and continuing ANC, gradual dose adjustment, bowel monitoring, cardiac and seizure risks, interactions and advice for missed doses. Ask who owns prescribing, test review and urgent questions. Pharmacy dispensing without REMS enrollment does not establish that those clinical responsibilities have been arranged.

Clozapine treatment and monitoring

Clozapine is an oral antipsychotic used for treatment-resistant schizophrenia. It also has an indication to reduce recurrent suicidal behaviour in people with schizophrenia or schizoaffective disorder at continuing risk. It is not a long-acting injection. FDA removed the clozapine REMS in June 2025, which changed dispensing administration. Blood monitoring and other safety checks remain part of clinical care.

Eligibility: Clozapine treatment and monitoring

The psychiatrist reviews adequate previous antipsychotic trials, adherence, symptoms and alternative explanations for nonresponse. Baseline absolute neutrophil count, known as ANC, is required under the label’s clinical instructions. Different thresholds apply to patients with documented Duffy-null associated neutrophil counts. Cardiovascular history, seizures, constipation, other medicines, infection and smoking patterns also matter.

What to expect: Clozapine treatment and monitoring

Review the reason for clozapine

Bring previous medicine names, doses, duration and response, plus hospital records. Clarify the intended indication and who will manage prescribing, laboratory review and urgent advice.

Create the monitoring and gradual start plan

The clinician chooses gradual titration and explains blood, vital-sign, bowel and other monitoring. With normal ANC, the label’s routine schedule is weekly during months one through six, every two weeks during months seven through twelve, then monthly. Abnormal results or interruptions can change this plan.

Keep daily safety and continuity checks

Report fever or infection symptoms, chest symptoms, severe constipation, marked dizziness, seizures or sedation promptly. Tell the prescriber before changing smoking, starting a medicine or stopping tablets. A missed dose is a medication-safety issue, not only a refill issue.

Preparing for your appointment

Bring recent blood results, a medicine list and previous treatment records. Explain your bowel pattern, constipation history, smoking and caffeine use, infections, heart problems and seizures. Ask who orders and reviews blood tests, what happens if a result is abnormal and how to obtain advice if a refill is delayed. A pharmacy’s ability to dispense does not establish that the clinical monitoring plan is in place.

Risks and when to seek help

Boxed warnings cover severe neutropenia, seizures, and low blood pressure on standing with a slow heartbeat or fainting. They also cover myocarditis, pericarditis and cardiomyopathy. Older adults with dementia-related psychosis have an increased mortality risk. Clozapine is not approved for that use. Severe constipation and gastrointestinal hypomotility can be life-threatening. Call 911 for chest pain, severe breathing difficulty, fainting or a seizure. Severe abdominal pain or constipation with vomiting needs emergency department care now. Call 911 if you cannot travel safely. Contact the team promptly about fever, infection symptoms or worsening bowel function.

Follow-up and treatment review

Do not resume the usual full dose after an interruption without prescriber advice. The current label reduces restart doses after even one or two missed days and uses a much lower start after longer gaps. The exact plan depends on the interruption and clinical situation. Keep ANC and other monitoring despite REMS removal, and report a change in smoking or infection because clozapine levels can change.

Appointments, costs and coverage

No REMS enrollment or submission of an ANC result to the REMS is now required for dispensing. The prescriber still needs an appropriate clinical monitoring and continuity plan. Ask about laboratory access, result review, pharmacy supply and medication costs. Confirm whether the selected team can manage clozapine prescribing, laboratory review and urgent interruptions before transferring care.

Questions about your care

Does clozapine still have a REMS program?

FDA removed the clozapine REMS in June 2025. That removes the REMS enrollment/reporting dispensing requirement; it does not remove the label’s ANC blood monitoring or other safety care. Continue the clinician’s laboratory and symptom-review plan.

Do I still need ANC blood tests? How often is ANC monitored? What happens if I miss several doses? Why should I report a change in smoking? What should I do with fever or infection symptoms?

Bring previous medicine names, doses, duration and response, plus hospital records. Clarify the intended indication and who will manage prescribing, laboratory review and urgent advice.

Can Nao continue clozapine prescribed elsewhere?

Bring your current clozapine prescription, recent blood counts, dose history and contact details for the treating psychiatrist. The clinicians must agree who will prescribe, arrange monitoring and respond to missed doses or symptoms. Do not interrupt or restart clozapine without a prescribing plan.

Why does constipation matter with clozapine?

Do I still need blood tests now that the REMS is gone?

Yes. FDA continues to recommend ANC monitoring according to the prescribing information. REMS removal changed enrollment and dispensing administration, not the risk of severe neutropenia.

Is clozapine a controlled substance or a second-generation antipsychotic?

Clozapine is an atypical, also called second-generation, antipsychotic. The US product record lists no DEA controlled-substance schedule. That does not make it a low-risk medicine. It requires a prescription, gradual dose changes and substantial safety monitoring. FDA’s June 2025 removal of the clozapine REMS ended the enrollment and reporting program. It did not remove the clinical need for absolute neutrophil count blood tests.

How does clozapine work?

Clozapine affects several brain receptor systems, including dopamine and serotonin receptors. Its exact therapeutic mechanism is not fully understood. It can help selected patients with schizophrenia that has not responded adequately to other antipsychotics. A separate indication is reducing recurrent suicidal behavior in certain patients with schizophrenia or schizoaffective disorder. Benefits must be weighed against its blood, heart, seizure, blood-pressure and bowel risks.

Can clozapine make me sleepy?

Yes. Drowsiness or sedation can occur with clozapine and may interfere with driving, work or safe daily activities. Avoid hazardous tasks until you know its effect on you. Alcohol and other sedating medicines can worsen impairment. Tell the prescriber if sleepiness is severe or affects caring for yourself; do not change the dose or restart after missed treatment on your own. Marked unresponsiveness, breathing difficulty or fainting needs urgent assessment.

Medical sources

A continuous clozapine care plan

1. Confirm diagnosis and prior treatment

Review prior antipsychotic trials, response, adverse effects, hospitalizations, suicidality, adherence, substance use, medical conditions, and treatment goals.

2. Establish a safe baseline

Review ANC, vital signs, weight and metabolic status, bowel function, cardiac symptoms and risk, seizures, smoking, medicines, pregnancy, and pharmacy access.

3. Start or continue with documented monitoring

The prescriber sets titration, dose, ANC frequency, symptom and side-effect checks, laboratory follow-up, and a plan for missed doses or abnormal results.

4. Respond early to warning signs

Fever, infection, severe constipation, chest pain, shortness of breath, fainting, seizures, marked sedation, or a treatment interruption need prompt clinical review.

Virtual psychiatry with coordinated local support